BROOKFIELD, Conn., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Photronics, Inc. (Nasdaq: PLAB), a worldwide leader in photomask technologies and solutions, is scheduled to announce financial results for the fourth quarter of fiscal 2025 on Wednesday, December 10, 2025, before the market opens. Photronics will host a public conference call the same day at 8:30 a.m. Eastern time. During the call, company management will respond to questions concerning, but not limited to, the company’s financial performance, business c ...

Core Insights - Cipher Mining Inc. has secured a 10-year high-performance computing (HPC) colocation agreement with Fluidstack, which is expected to generate approximately $830 million in contracted revenue over the initial term [1][3] - The total contracted revenue across the partnership is projected to reach around $3.8 billion over the initial 10-year term, with potential extensions increasing this figure significantly [3][7] - Google has expanded its backstop of Fluidstack's obligations by an additional $333 million, raising the total backstop to $1.73 billion [1][4] Transaction Details - Cipher will provide an additional 39 MW of critical IT load at its Barber Lake site, supported by a maximum of 56 MW of additional gross capacity [2] - If the two five-year extension options are exercised, the total contracted revenue for this transaction could reach approximately $2.0 billion, and up to $9.0 billion for the entire lease [3][7] - The expected site net operating income (NOI) margin is estimated to be between 85% and 90% [7] Financial Aspects - Estimated project costs are approximately $9-$10 million per MW of critical IT load [7] - Cipher has committed financing in place and plans to use proceeds from project-related debt along with about $118 million in additional equity contributions for the construction of incremental facilities [4][7] Company Positioning - Cipher's CEO expressed excitement about expanding partnerships with Fluidstack and Google, highlighting the company's leadership in HPC development and growth momentum across its pipeline of sites [5]

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced that it is seeking authorization to initiate a new Ordinary Share repurchase program (“new repurchase program”) for up to $40 million, which would commence following the completion of its current program. The new repurchase program is intended to capitalize on what the Company believes ...

Core Viewpoint - Xtract One Technologies Inc. is set to release its fiscal 2026 first quarter results on December 3, 2025, with a subsequent conference call scheduled for December 4, 2025, to discuss the financial outcomes and future outlook [1][2]. Company Overview - Xtract One Technologies is a leader in technology-driven threat detection and security solutions, utilizing AI to enhance patron access experiences [3]. - The company specializes in unobtrusive weapons and threat detection systems aimed at improving safety while facilitating smooth access for patrons [3]. - Xtract One's AI-powered Gateway solutions are designed to discreetly screen for weapons and threats at entry and exit points, catering to various sectors including schools, hospitals, and stadiums [3]. Industry Context - The threat detection solutions provided by Xtract One are part of a multilayered approach to physical security, acknowledging that no single system can guarantee 100% effectiveness against all potential threats [4].

Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potentialIn September 2025, Sol-Gel announced Health Canada approval of EPSOLAYSol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO NESS ZIONA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments fo ...

HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Humana, Inc. (NYSE: HUM), effective October 29, 2025, covering approximately 16 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory developed test (LDT). This brings CNSide CSF TCE LDT total policy coverage ...

Company completes exit from modular home construction, expands into containerized energy systems, and advances vertically integrated model spanning power generation, data centers, bitcoin mining, and modular micro-refineries.The following is a letter to shareholders from the CEO of Safe & Green Holdings Corp. CONROE, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- via IBN -- Safe & Green Holdings Corp. (NASDAQ: SGBX) (“Safe & Green” or the “Company”) -- As we approach one year since Olenox/NAHD assumed an active l ...

Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiaryPartnership expected to expand BriaPro's small-molecule pipeline Aims to accelerate the development of next generation therapeutics with improved efficacy and safety PHILADELPHIA and VANCOUVER, British Columbia and BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-sta ...

EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU  AUSTIN, Texas, November 20, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for new ultrasound imaging and workflow enhancements to the Focal One High Intensity Focused Ultrasound (HIFU) system, further strengthening the company’s market leadership in robotic focal therapy for prostate cancer. ...

New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued treatment, and real-world experienceBiogen is committed to deepening scientific understanding of Alzheimer’s disease, including therapeutic delivery and disease progression CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 18th Clini ...